Toru Ishikawa

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji et al. · Liver Cancer · 2018 · 230 citations · Full text

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo et al. · Liver Cancer · 2017 · 208 citations · Full text

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa et al. · Cancer Medicine · 2019 · 158 citations · Full text

Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo et al. · Digestive Diseases · 2017 · 144 citations

Surgical Oncology, Sorafenib Treatment, Pathology +21

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama et al. · Cancer Medicine · 2018 · 130 citations · Full text